The main objective of this work was to develop a simple, rapid and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of Canagliflozin and Metformin. Methods: Deuterated compounds of respective drugs were used an internal standard. Sample extraction was carried out using a simple Protein Precipitation (PP) technique. A C 18 column with an isocratic mobile phase composed of 5mM ammonium acetate with 0.01% formic acid and methanol were used for chromatographic separation. Results: The method was validated in the linearity range of 10.00-6028.00 ng/mL for Canagliflozin and 10.00-3027.00 ng/mL for Metformin. The precision and accuracy results over five concentration levels in five different batches were well within the acceptance limits. A variety of stability tests were executed in plasma and in neat samples are comply with the FDA guidelines. Conclusion: The proposed assay method is simple, rapid and sensitive for the simultaneous determination of Canagliflozin and Metformin in human plasma. This method was successfully used to quantitate the in vivo plasma concentrations obtained from a pharmacokinetic study.
INTRODUCTION
Type 2 Diabetes (T2DM) is a complex metabolic disorder characterized by impaired insulin secretion and impaired insulin action. 1 Chronic hyperglycaemia and uncontrolled glucose levels results T2DM progression and enhanced risk of complications and mortality. To achieve optimal glucose, control it is often necessary to rely on combination therapy of multiple drugs or insulin. 2 Canagliflozin, a Sodium-glucose co-transporter 2 (SGLT2) inhibitor used to manage T2DM. By inhibiting SGLT2, Canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RT G ) and thereby increases urinary glucose excretion. 3 It is used as an adjunct to diet and exercise. [3] [4] [5] Metformin is one of the most commonly prescribed drug worldwide for T2DM therapy. Metformin lowers both basal and Postprandial Plasma Glucose (PPG) and improving the glucose uptake and utilization. Metformin has additional benefits like weight reduction, lowering lipid levels and prevention of some vascular complications. [6] [7] [8] Metformin is a first-line therapy for patients with T2DM. Though, many patients do not achieve effective glycemic control with Met-formin alone and require subsequent combination therapy with other antihyperglycemic agents. The American Association for Clinical Endocrinologists algorithm for the treatment of T2DM recommends Metformin plus SGLT2 inhibitor as the first oral combination in patients with HbA1c ≥7.5% for a better glycemic control. Canagliflozin in combination with Metformin provided more glycemic control than monotherapy. 9,10 INVO-KAMET TM (Janssen Pharmaceuticals, Inc.) a combination of Canagliflozin and Metformin is available in the market with variable dosing. Many analytical methods were reported in literature for the determination of Canagliflozin 5, 11 and Metformin [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] individually or with some other drugs in biological samples. These methods are only suitable for quantitation of one drug in biological samples selectively and sensitively may not be suitable for simultaneous quantification Canagliflozin and Metformin. Analysis of Canagliflozin and Metformin in a single run is challenge due to their different physiochemical properties. To address the pharmacokinetics of the new combined formulation, a sensitive and specific method that allows simultaneous measurement of Canagliflozin and Metformin in human plasma is needed. Recently, Shah et al. 2018 23 published a LC-MS/MS method for the simultaneous determination of Canagliflozin and Metformin in plasma samples. Though the method is sensitive, the total run time was more than 4 min and complex with the use of ion pairing agents during sample preparation. In the present work, the authors developed a simple, sensitive and selective LC-MS/MS assay method for the determination of Canagliflozin and Metformin in human plasma using isotope labelled internal standards Canagliflozin d4 (IS1) and Metformin d6 (IS2), respectively. These internal standards minimize the matrix effect related problems and variability in recovery between analyte and the IS. The method requires only 100 µL human plasma for simple and one step Protein Precipitation (PP) technique demonstrates excellent performance in terms of ruggedness with a sample cut off time 2.5 min for simultaneous quantification of Canagliflozin and Metformin. The validated method was successfully applied to a human pharmacokinetic study.
MATERIALS AND METHODS

Standards and chemicals
Reference samples of Canagliflozin (99.96%), Metformin hydrochloride (100.10%), Canagliflozin d4 (97.55%) and Metformin d6 hydrochloride (99.88%) were obtained from Clearsynth Labs Limited, India. LC-MS/MS grade water was prepared from inhouse water purification system (Millipore, Bangalore, India) and blank plasma obtained from blood bank (Deccan's labs, Hyderabad, India). Formic acid and ammonium acetate were purchased from Merck Ltd (Mumbai, India). Similarly, high purity solvents of acetonitrile and methanol was purchased from J.T Baker (Phillipsburg, USA).
LC-MS/MS instrument and conditions
A triple quadrupole API-4000 mass spectrometer (AB Sciex, Foster City, CA, USA) coupled with HPLC (Shimadzu Corporations, Kyoto, Japan) was used for the present study. The processed samples were chromatographed on a Hypersil BDS, C 18 (100 × 4.6 mm, 5 µm) column using an isocratic mobile phase composed of 5mM ammonium acetate with 0.01% formic acid and methanol (15:85, v/v). The flow rate was set at 1.0 mL/min and the injection volume was 15µL. The optimized mass spectrometric conditions are summarized in the Table 1 .
Preparation of spiked plasma samples
All the stock solutions were prepared in methanol, separately and further dilutions were prepared in 40:60, v/v of water and acetonitrile (diluent). Stock solutions were stored in refrigerator at 2-8°C for 45 days. Calibration standards and quality control samples were prepared from two independent weighing of the respective standards. Calibrates were prepared at concentrations of 10 
Sample preparation procedure
The frozen samples were thawed at room temperature and vortexed to ensure complete mixing of the contents. An aliquot 100 µL of plasma sample was pipetted into prelabelled 5mL polypropylene tubes and 15 µL of internal standard dilution (a combined dilution of 30 µg/mL and 15 µg/mL of Canagliflozin d4 and Metformin d4, respectively) was added to it. After vortexing for 15 sec, 3mL of acetonitrile was added to each sample and vortexed for 30 sec, then centrifuged at 4000rpm for 10 min at 4°C. 2 mL of supernatant layer was transferred to prelabelled glass test tubes and evaporated to dryness at 45°C under gentle stream of nitrogen. The dried extract was reconstituted with 500 µL of the mobile phase and injected.
Method validation
The following validation tests were conducted as per the recent U.S Food and Drug Administration (US FDA) 24 guidelines: carryover test, system suitability, matrix effect, selectivity, precision and accuracy, linearity, long run evaluation, dilution integrity, ruggedness and stability studies.
Pharmacokinetic study design
A pharmacokinetic study was performed in healthy male subjects (n=6). Informed consent was obtained from each subject. All the subjects were selected based on their body-mass index (BMI) of ≥18.5 kg/m 2 and ≤24.9 kg/m 2 , with body weight not less than 50 kg. Medical history of the subjects was considered before inclusion in study. The subjects were tested for clinical tests such as hepatic and renal profile, blood glucose levels, whole blood count and screened for infectious diseases like HIV 1 and 2, HbsAg (Hepatitis-B) and HCV (Hepatitis-C). Blood samples (4 mL) were collected following oral administration of 150 mg tablet of Canagliflozin and 500 mg tablet of Metformin hydrochloride at pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.5, 5, 6, 8, 10, 12, 16, 24, 36, 48 and 72 h in K2-EDTA vacutainer collection tubes (BD, Franklin, NJ, USA). The blood samples were centrifuged at 4000 rpm for 10 min and the plasma was collected. The plasma samples were stored at -70 ± 10°C till their analysis. Plasma concentration-time profile of each analyte was analyzed by non-compartmental method using WinNonlin Version 5.1.
RESULTS AND DISCUSSION
Method development
The aim of the present study was to develop and validate a rapid and sensitive LC-MS/MS method for the simultaneous determination of Canagliflozin and Metformin in human plasma. Mass parameters were tuned in both positive and negative ionization modes for the analytes. The response obtained for Canagliflozin was low and not enough to quantify in positive and negative mode. Hence, as described in the earlier report 5 intensity of ammonium adduct (M+NH 4 ) + of Canagliflozin was monitored. Data acquisition was performed in the Multiple Reaction Monitoring (MRM) mode to obtain better selectivity. The source dependent parameters such as curtain gas, collision gas, GS1 and GS2 were suitably altered to get satisfactory and reproducible response. Similarly, compound dependent parameters namely Collision Energy (CE), Declustering Potential (DP) and collision cell exit potential (CXP) were altered to get most intense and consistent product ion Q3 MS spectra of analytes. The positive ion spray mass spectrum shown a protonated molecular species by monitoring the transition pairs of m/z 462 precursor ion to the m/z 267 for Canagliflozin, m/z 130 precursor ion to the m/z 71 product ion for the Metformin, m/z 466 precursor ion to the m/z 267 product ion for Canagliflozin-d4 and m/z 136 precursor ion to the m/z 77 product ion for Metformin-d4. Data integration was performed with Analyst Software™ (version 1.4.2). The important chromatographic conditions such as mobile phase composition, analytical column type and flow rate were carefully monitored to obtain the good resolution from the endogenous components and better peak shape. The widely used buffers in mass spectrometry analysis are ammonium formate and ammonium acetate and acid modifiers are formic acid and acetic acid due to their volatility and ease of evaporation. Similarly, widely used organic solvents are acetonitrile and methanol. Hence, the mobile phase composition was elevated with acetonitrile and methanol by varying its proportion with above mentioned volatile buffers at different strengths. Additionally, a variety of analytical columns (Hypersil BDS, Kromasil C 8 ; Zodiac C 18 , Zorbax SB C 18 , Zorbax XDB-phenyl; Zorbax SB C 8 , Hypurity Adavance, Inertsil ODS, etc) were tested for better selectivity and sensitivity of an assay. An isocratic mobile phase composition with acetonitrile/ methanol and ammonium formate (5 and 10mM)/formic acid buffer (0.01 and 0.03%) was tested at different flow rates (0.5, 0.7 and 1.0 mL/min). But area response was not reproducible with bad peak shape especially for metformin. Therefore, ammonium acetate was tested in combination with methanol and acetonitrile using above mentioned analytical columns. A combination of ammonium acetate with methanol gave better peak shape and response compared to above listed solvents. Analytes response was significantly increased by adding 0.01% formic acid to ammonium acetate buffer. Among the various chromatographic columns tested for their suitability Hypersil BDS C 18 (100*4.6mm, 5 µm) column gave better peak shape for Canagliflozin and Metformin with retention time of 1.5 and 1.8 min, respectively. The shortest run time of 2.5 min was achieved with flow rate of 1.0 mL/min. The quality of sample preparation significantly impacts the mass spectrometry results. Presence of endogenous compounds in the extracted sample decreases the mass spectrometric performance. SPE is an efficient extraction method to remove the endogenous components from biological samples. But it requires many stringent method development protocols, equipment's and expensive. We aimed to develop a simple and efficient extraction method, PP was tested. PP with acetonitrile and methanol was tested. Highest recoveries for Canagliflozin and Metformin was obtained with acetonitrile compared to methanol. Deuterated standards of Canagliflozin and Metformin were used as internal standards to increase the precision and to decrease the variability in recovery.
Carryover test, selectivity, sensitivity and matrix effect
A mixture of methanol and acetonitrile (50:50, v/v) was used as rinsing solution. No noticeable carryover was observed in successive blank sample runs after injection of ULOQ sample of both the analytes. A system suitability test was performed every day before start of analysis and the precision (%CV) for response ratio of both the analytes were less than 1.5%. All the blank plasma lots tested were free from significant interfere at the retention time of Canagliflozin and Metformin. The representative extracted blank plasma chromatograms were shown in Figure 1 . Similarly, no significant interference was observed from the respective internal standards at the MRM channels of the analytes.
Limit of Quantitation (LOQ) for Canagliflozin and
Metformin was set at 10.27 ng/mL and 10.03 ng/mL, respectively ( Figure 2 ). The precision (% CV) and accuracy at this concentration was 1.75 and 103.10% and 3.23 and 93.61% for Canagliflozin and Metformin, respectively. Also, at LOQ concentration, the signalto-noise ratio for Canagliflozin and Metformin were above 1:10. The average IS normalized matrix factor value calculated at LQC and HQC levels was found to be 1.01 and 1.01 for Canagliflozin and 0.99 and 1.00 for Metformin, which shows negligible ion suppression or enhancement. Similarly, the precision (%CV) at LQC and HQC levels was found to be 2.08 and 0.37% for Canagliflozin and 2.64 and 0.75% for Metformin. 
Linearity, precision and accuracy
A total of five calibration curves containing five QC concentration levels covering the whole linearity range were run in three different days. Of the above, one calibration curve with QC samples were analyzed using set of reagents and with different analyst to establish the method ruggedness. The calibration curve was found to be linear over the concentration range of 10.27-6028.07 ng/mL for Canagliflozin and 10.03-3027.28 ng/mL for Metformin. The mean correlation coefficient values were ≥ 0.99 for Canagliflozin and Metformin. After comparing the two weighting models (1/x and 1/x 2 ) and a regression equation with a weighting factor of 1/x 2 was found to establish the best relationship between concentration-detector response.
The intra-day and inter-day precision and accuracy results are presented in Table 2 . The precision results in both the occasions for Canagliflozin and Metformin was less than 15% and accuracy was 100 ± 15% of the actual values at LQC, MQC-1, MQC-2 and HQC level, whereas at LLOQ QC level the precision was less than 20% and accuracy was 100±20%.
Recovery and dilution integrity
The simple PP with acetonitrile gives highest recovery for Canagliflozin and Metformin. The mean extraction recovery with precision range for Canagliflozin, Metformin, IS1 and IS2 were 81.72% (0.56-4.09%), 88.77% (1.41-5.52%), 90.55% (4.58-5.44%) and 90.38% (3.07-7.61%), respectively. The dilution integrity experiment was conducted to increase the upper limit of quantitation if needed. A set of samples were prepared by spiking (about 3.3 times of ULOQ) Canagliflozin and Metformin at concentration of 20103.16 ng/mL and 10301.54 ng/mL and stored at -70°C overnight prior to analysis. Six aliquots were diluted to two folds and four folds dilution with screened human blank plasma. The results of two and four-fold dilutions for both the analytes were well within the limits.
Stability studies
In the different stability experiments carried out viz. bench top stability (20 hr), auto-sampler stability at 5°C (55 h) repeated freeze-thaw cycles (4 cycles), postprocessing sample stability (50 h at 2-8°C) Re-injection reproducibility (45 hr) and long term stability at -70°C for 75 days the mean % nominal values of the analyte were found to be within ±15% of the predicted concentrations for the analyte at their LQC and HQC levels (Table 3) . Thus, the results were found to be within the acceptable limits during the entire validation.
Pharmacokinetic results
The validated method was successfully used to determine the in-vivo sample concentrations of Canagliflozin and Metformin obtained from a pharmacokinetic study. A representative chromatogram resulting from the analysis of 0.75 h subject plasma sample of Canagliflozin and Metformin is shown in the Figure 3 . Similarly, the mean concentration-time profiles of a single oral dosage Canagliflozin (150mg) and Metformin (500mg) after a single oral dosage is shown in Figure 4 and the corresponding pharmacokinetic parameters are listed in Table 4 . Pharmacokinetic parameters of the Canagliflozin are dose comparable with the values reported earlier. 5 Similarly, pharmacokinetics of Metformin were in close proximity to the values reported by earlier researchers. 14
CONCLUSION
We have developed a rapid and sensitive LC-MS/MS method for simultaneous quantification of Canagliflozin and Metformin in human plasma using stable labelled isotopes as internal standards. The method was fully validated as per Guidelines for Industry, Bioanalytical Method Validation, U.S. Food and Drug Administration. The method employs simple and one step PP for samples preparation using 100µL of the plasma volume and obtained highest recovery for the analytes. The stability Canagliflozin and Metformin in plasma as well as in processed samples have been extensively evaluated and obtained results were acceptable in all the specified conditions. The method was found to be reliable and reproducible to support a pharmacokinetic and bioequivalence study in healthy volunteers.
